TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9920455
Drug: N‐nitro‐L‐arginine methyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐nitro‐L‐arginine methyl ester (L‐NAME) 40 mg/kg injected plus 50 mg/kg infused over 60 min
Study: 8049459
Drug: Initial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial therapy
Study: 3393023
Drug: Intensive maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive maintenance therapy (chemotherapy: cytosine arabinoside plus 6-thioguanine, 100 mg/m2 every 12 hr for a variable number of days, repeated every three months for three or more years)
Study: 3393023
Drug: Splenectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Splenectomy plus chemotherapy (control group)
Study: 3393023
Drug: Immunotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy plus chemotherapy (control group)
Study: 29853416
Drug: Single Infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single Infusion (SI) - 0.2 mg kg−1 minute−1 for 240 minutes after a bolus of 2 mg kg–1
Study: 29853416
Drug: 3-step Infusion
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-step Infusion - 0.4 mg kg−1 minute−1 for 10 minutes, then 0.3 mg kg−1 minute−1 for 30 minutes, and then 0.2 mg kg−1 minute−1 for 200 minutes after a bolus of 2 mg kg–1
Study: 22004585
Drug: Oral EDTA-Na-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral EDTA-Na-Fe (60 mg Fe/dose, three times a week) and a 2-week course of colloidal bismuth subcitrate, amoxicillin and metronidazole
Study: 18823410
Drug: Oral insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin intervention
Study: 18823410
Drug: Placebo vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vs. active drug assignment
Study: 12079930
Drug: Routine dose
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine dose of thyroxin administered orally or via nasogastric tube in the perioperative period, no supplemental dose used.
Study: 9617439
Drug: Intracutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injection of vasoactive intestinal polypeptide (VIP) at concentrations of 1.5 x 10(‐7), 1.5 x 10(‐6), and 1.5 x 10(‐5) M; combined with acetylcholine (ACh) at 5.5 x 10(‐6) M.
Study: 9617439
Drug: Intracutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injection of VIP and ACh
Study: 9617439
Drug: ACh administration
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACh administration
Study: 9161245
Drug: One-stage, nonsubmerged
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-stage, nonsubmerged ITI implants
Study: 11181673
Drug: Paclitaxel 200
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 200 mg/m(2) + cisplatin 75mg/m(2) + granulocyte colony-stimulating factor (Arm A)
Study: 11181673
Drug: Paclitaxel 135
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 135 mg/m(2) + cisplatin 75 mg/m(2) (Arm B)
Study: 9037637
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (3 micrograms/kg per min)
Study: 3827416
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 10 mg administered sublingually
Study: 3827416
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 10 mg administered sublingually after 120 minutes to placebo-pretreated patients
Study: 3827416
Drug: Conventional antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antihypertensive medications and bed rest (Control)
Study: 23159232
Drug: No darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No darbepoetin alfa doses
Study: 23159232
Drug: 1 dose
Normalized name: Ribose 3 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of darbepoetin alfa
Study: 23159232
Drug: 2-4 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-4 doses of darbepoetin alfa
Study: 23159232
Drug: 5 or
Normalized name: Acys-5 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 or more doses of darbepoetin alfa
Study: 17904834
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with salmeterol and fluticasone
Study: 16614542
Drug: Topiramate 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 25, 50, and 100 mg daily
Study: 12657970
Drug: Corticosteroid infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid infusion for 48 hours after significant head injury
Study: 8436235
Drug: Sterile vaseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile vaseline ointment
Study: 30293467
Drug: Dezocine-based local
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dezocine-based local anesthesia (preoperative intramuscular injection of dezocine)
Study: 30293467
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dezocine injection)
Study: 24884578
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (vancomycin or anti-staphylococcal penicillin)
Study: 27629750
Drug: Berberine treatment
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine treatment
Study: 28176235
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg SC sumatriptan (DFN-11)
Study: 16151760
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg SC sumatriptan
Study: 23423871
Drug: Pulsed dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed dye laser (PDL) plus topical tazarotene 0.1% cream
Study: 15057741
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a 180 microg/wk plus ribavirin 1000-1200 mg/day
Study: 15057741
Drug: Ribavirin dose
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin dose reduction from > or =80% to < or =60% of the starting dose during the first 20 weeks of treatment
Study: 15057741
Drug: Peginterferon or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon or ribavirin dose reduction after week 20
Study: 9663362
Drug: Venlafaxine 37.5
Normalized name: venlafaxine 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 37.5 mg twice daily (increased to 75 mg if needed)
Study: 9663362
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once daily (increased to 40 mg if needed)
Study: 30912213
Drug: 50:50 mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50:50 mixed analog insulin (Humalog® Mix50/50™)
Study: 30912213
Drug: 30:70 mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30:70 mixed human insulin
Study: 26165264
Drug: Implant removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant removal
Study: 26165264
Drug: No implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No implant removal (Control)
Study: 21607821
Drug: Extralight titanized
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extralight titanized polypropylene mesh (ELW group) TiMesh(®) 16 g/m(2) without any fixation
Study: 21607821
Drug: Standard heavyweight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heavyweight polypropylene mesh (HW group) Prolene 90 g/m(2) fixed with two absorbable sutures
Study: 16438762
Drug: Esomeprazole 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 3 x 40 mg
Study: 12559678
Drug: hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydrochlorothiazide (HCTZ) (25 mg)
Study: 11436909
Drug: Narcotic analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narcotic analgesia administered in the emergency department (ED)
Study: 7530026
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies to HIVLAI
Study: 20825901
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (including furosemide, oxygen, and high-dose boluses of isosorbide dinitrate)
Study: 19515413
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once a day
Study: 19515413
Drug: Exenatide 10
Normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 10 microg twice a day
Study: 15612859
Drug: High-dose nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nicotine (35 mg) patch
Study: 11282204
Drug: Meningococcal serogroup
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal serogroup C conjugate vaccine (MenC)
Study: 3081923
Drug: Yohimbine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (30 mg)
Study: 3081923
Drug: Alprazolam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.5 mg) and Yohimbine (30 mg) together
Study: 23090523
Drug: Hydrocodone-acetaminophen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-acetaminophen (10 mg hydrocodone and 650 mg acetaminophen)
Study: 23090523
Drug: Hydrocodone-acetaminophen
Normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone-acetaminophen
Study: 16124155
Drug: Nerve stimulator-guided
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulator-guided and double-injection (ND) group
Study: 16124155
Drug: Ultrasound-guided and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided and double-injection (UD) group
Study: 16124155
Drug: Ultrasound-guided and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided and single-injection (US) group
Study: 8619007
Drug: DN-2327 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DN-2327 (3 mg)
Study: 23672055
Drug: Alprazolam (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.8 mg)
Study: 8619007
Drug: DN-2327 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DN-2327 (2 mg)
Study: 2057271
Drug: Non-hypnotic distraction/relaxation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hypnotic distraction/relaxation
Study: 29402064
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous alteplase (0.6 mg/kg)
Study: 29402064
Drug: Standard-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose intravenous alteplase (0.9 mg/kg)
Study: 23394510
Drug: Routine ED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine ED treatment including oral prednisone at 60 mg and inhalation of nebulized albuterol and ipratropium
Study: 24200100
Drug: Conventional Treatment
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatment (CT)
Study: 10480222
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein supplement (7.8 g/d)
Study: 9124982
Drug: Cefpirome treatment
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome treatment for wound infections
Study: 9124982
Drug: Cefpirome treatment
Normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome treatment for burn infections
Study: 1832209
Drug: Methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone acetate (20 mg)
Study: 11842065
Drug: 3.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g/kg of [(13)C]glucose (approximately 2 g/min)
Study: 3302110
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg/day
Study: 9818846
Drug: Gabapentin 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,800 mg/day
Study: 7981446
Drug: OC users
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC users with low estrogen receptor content
Study: 7981446
Drug: OC users
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC users with low progesterone receptor content
Study: 31426673
Drug: Standard-of-care endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care endocrine monotherapy treatment (fulvestrant or an aromatase inhibitor, per investigator's choice)
Study: 19764666
Drug: Single layer
Normalized name: Bayer Aspirin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single layer closure (closure of skin and subcutaneous tissues together)
Study: 19764666
Drug: Two layer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two layer closure (closure of skin and subcutaneous tissues separately)
Study: 9532327
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g every 8 hours for 3-14 days, average 9 days)
Study: 9532327
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g every 8 hours) and Amikacin (0.5 g every 12 hours for 2-14 days, average 9 days)
Study: 31707500
Drug: Daily symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily symptom screening using the SPARK platform
Study: 28954640
Drug: β2‐1 fructan
Approvals — FDA: no, EMA: no, PMDA: no
Description: β2‐1 fructan (3×5 g/d)
Study: 28954640
Drug: Maltodextrin (3×5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (3×5 g/d)
Study: 20945252
Drug: Implementation intention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Implementation intention intervention to increase fruit and vegetable intake by two extra portions daily over 7 days
Study: 11386392
Drug: Therapy plus
Normalized name: Lubriderm Advanced Therapy Plus Ceramide Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy plus imagery (10-minute guided imagery sessions after each therapy session, plus home practice twice weekly)
Study: 11386392
Drug: Therapy only
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy only (control group)
Study: 10359885
Drug: R-salbutamol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-salbutamol 1.25 mg
Study: 10359885
Drug: Racemic salbutamol
Normalized name: EPINEPHRINE,RACEMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic salbutamol 2.5 mg
Study: 10359885
Drug: S-salbutamol 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-salbutamol 1.25 mg
Study: 27302721
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) provided by a bilingual social worker
Study: 24843974
Drug: Blank group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank group (no treatment before surgery)
Study: 19014834
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg + Simvastatin 40 mg
Study: 19014834
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg + Simvastatin 20 mg
Study: 19014834
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg + Simvastatin 40 mg
Study: 19014834
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg + Simvastatin 20 mg
Study: 19014834
Drug: Valsartan 160/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160/320 mg + Simvastatin 20 mg
Study: 19014834
Drug: Valsartan 160/320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160/320 mg + Simvastatin 40 mg
Study: 16898379
Drug: Alternative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapy failure criteria
Study: 16898379
Drug: WHO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: WHO therapy failure criteria
Study: 11185634
Drug: Oral telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telmisartan 20 mg
Study: 11185634
Drug: Oral telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telmisartan 120 mg
Study: 11185634
Drug: Intravenous telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous telmisartan 120 mg
Study: 11185634
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and i.v. telmisartan
Study: 11185634
Drug: Oral telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral telmisartan
Study: 8858631
Drug: Subconjunctival mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival mitomycin-C (MMC) administration (0.27 mg/ml for 5 minutes)
Study: 8858631
Drug: Intrascleral mitomycin-C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrascleral mitomycin-C (MMC) administration (0.27 mg/ml for 5 minutes)
Study: 1298601
Drug: Selenium yeast
Normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium yeast 200 g Se1Tab/day
Study: 29608685
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (control arm)
Study: 26869191
Drug: Omarigliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omarigliptin (50 mg, once weekly for 4 weeks)
Study: 15809885
Drug: Deferiprone 75
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone 75 mg/kg daily for 12 months
Study: 12027845
Drug: ondansetron 16
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 16 mg
Study: 329741
Drug: Cyclophosphamide as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide as a single agent
Study: 329741
Drug: Actinomycin D‐‐vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actinomycin D‐‐vincristine combination
Study: 329741
Drug: Cyclophosphamide‐‐methotrexate‐‐vincristine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide‐‐methotrexate‐‐vincristine combination
Study: 16566622
Drug: Imipramine (209
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (209 mg/day, SD: 91.7, range: 75-325 mg/day)
Study: 9777685
Drug: Immunochemotherapy as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunochemotherapy as an adjuvant treatment after curative resection of gastric cancer
Study: 3344781
Drug: Anterior chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior chamber lenses with posterior capsule left intact
Study: 3344781
Drug: Anterior chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior chamber lenses with ruptured posterior capsule
Study: 28197749
Drug: Lifestyle-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle-based training (two weekly group sessions lasting 60-90 minutes)
Study: 26164666
Drug: 2-L PEG
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L PEG plus bisacodyl
Study: 21071497
Drug: Deferasirox therapy
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferasirox therapy
Study: 23590671
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no deferasirox therapy)
Study: 10868020
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of Triamcinolonhexacetonide
Study: 27281799
Drug: Immediate-release arginine
Normalized name: arginine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release arginine (IR-Arg) 1.5 g, 3 times/day
Study: 27281799
Drug: Sustained-release arginine
Normalized name: arginine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release arginine (SR-Arg) 1.5 g, 3 times/day
Study: 27281799
Drug: Sustained-release arginine
Normalized name: arginine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release arginine (SR-Arg) in HTW subjects
Study: 27281799
Drug: Immediate-release arginine
Normalized name: arginine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release arginine (IR-Arg) in HTW subjects
Study: 27281799
Drug: Sustained-release arginine
Normalized name: arginine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release arginine (SR-Arg) in CON subjects
Study: 12438559
Drug: ISIS 104838
Normalized name: ISIS 104838
DrugBank: ISIS 104838 (DB16201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered intravenously (i.v.) at doses of 0.1-6 mg/kg
Study: 12438559
Drug: ISIS 104838
Normalized name: ISIS 104838
DrugBank: ISIS 104838 (DB16201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered intravenously (i.v.)
Study: 12438559
Drug: ISIS 104838
Normalized name: ISIS 104838
DrugBank: ISIS 104838 (DB16201)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 104838 (20‐mer phosphorothioate antisense oligonucleotide) administered subcutaneously (s.c.)
Study: 7562881
Drug: Slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nifedipine 20 mg twice daily for 4 weeks
Study: 1710802
Drug: Carbimazole (antithyroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole (antithyroid drug) for 18 months